These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29172661)

  • 1. [Novelties in the treatment of pediatric immune thrombocytopenia - 2017].
    Kovács G; Kiss C
    Orv Hetil; 2017 Dec; 158(48):1891-1896. PubMed ID: 29172661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eltrombopag with i.v. immunoglobulin for safe splenectomy in refractory immune thrombocytopenia.
    Kanno M; Onoda T; Meguro T; Sato H; Mitsui T
    Pediatr Int; 2018 Feb; 60(2):191-192. PubMed ID: 29271533
    [No Abstract]   [Full Text] [Related]  

  • 3. A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia.
    Grainger JD; Thind S
    Pediatr Hematol Oncol; 2017 Mar; 34(2):73-89. PubMed ID: 28537785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
    Depré F; Aboud N; Mayer B; Salama A
    PLoS One; 2018; 13(6):e0198184. PubMed ID: 29856800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New treatment options for primary immune thrombocytopenia].
    Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.
    Burness CB; Keating GM; Garnock-Jones KP
    Drugs; 2016 May; 76(8):869-78. PubMed ID: 27151255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag for resistant immune thrombocytopenia secondary to chronic lymphocytic leukaemia.
    Jolliffe E; Romeril K
    Intern Med J; 2014 Jul; 44(7):697-9. PubMed ID: 25041772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U.S. Food and Drug Administration approval summary: Eltrombopag for the treatment of pediatric patients with chronic immune (idiopathic) thrombocytopenia.
    Ehrlich LA; Kwitkowski VE; Reaman G; Ko CW; Nie L; Pazdur R; Farrell AT
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28627134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of eltrombopag in a child with refractory immune thrombocytopenia: case study and literature review.
    Wang XL; Li AM
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):825-827. PubMed ID: 26650460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Thrombocytopenia Resolved by Eltrombopag in a Carrier of Glucose-6-Phosphate Dehydrogenase Deficiency.
    Scaramucci L; Niscola P; Palombi M; Tendas A; Giovannini M; Fabritiis Pd
    Turk J Haematol; 2016 Mar; 33(1):77-8. PubMed ID: 27091587
    [No Abstract]   [Full Text] [Related]  

  • 14. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
    Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
    Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B;
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract]   [Full Text] [Related]  

  • 17. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.